Thromb Haemost. 2022;122(1):160-162.
De-escalation of Prasugrel Results in Higher Percentage of Patients within Optimal Range of Platelet Reactivity: Analysis from the HOST-REDUCE-POLYTECH-ACS Trial.
제1저자 이학승 · 교신저자 박경우
소속 (1)
- Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea.
Conflict of interest statement
H-.S.K. has received research grants or speaker's fees from Daiichi Sankyo, Boston Scientific, Terumo, Biotronik, and Dio, as well as Medtronic, Abbott Vascular, Edwards Life Science, AmGen, and Boehringer Ingelheim. K.W.P. reports fees from Daiichi Sankyo, Astra-Zeneca, Sanofi, Bristol-Myers Squibb, Bayer AG, and Pfizer outside of the submitted work. All other authors declare no competing interests.
그 밖의 정보
- 출판 형태
- Letter, Multicenter Study
- 저널
- Thrombosis and haemostasis · eISSN 2567-689X
- 전자 출판
- 2021-06-21
- MeSH
- Aged · Blood Platelets / drug effects / physiology · Dose-Response Relationship, Drug* · Female · Humans · Male · Middle Aged · Platelet Aggregation Inhibitors / pharmacology / therapeutic use · Prasugrel Hydrochloride / pharmacology / therapeutic use · Republic of Korea / epidemiology · Treatment Outcome
- Substances
- Platelet Aggregation Inhibitors · Prasugrel Hydrochloride